Neuropsychopharmacology - Improvement of the Rett syndrome phenotype in a MeCP2 mouse model upon treatment with levodopa and a >>


Molecular Cell - Liz J, Portela A, Soler M, Gómez A, Ling H, Michlewski G, Calin GA, Guil S, Esteller M. >>


Nature Communications - A DERL3-associated defect in the degradation of SLC2A1 mediates the Warburg effect. Lopez-Serra P, M >>


Cell Reports - Linkage of DNA Methylation Quantitative Trait Loci to Human Cancer Risk.Heyn H, Sayols S, Moutinho C >>


Cancer Discovery - MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal wit >>


Genome Research - DNA methylation contributes to natural human variation. Heyn H, Moran S, Hernando-Herraez I, Sayols  >>


Genes & Development - Serrano, L., Martinez-Redondo, P., Marazuela-Duque, A., Vazquez, B.N., Kane-Goldsmith, N., Dooley, S >>



Help us to investigate new treatments for children affected by Rett Syndrome: our new Crowdfunding Project in Verkami.

Dr Manel Esteller

The Rett Syndrome is the second most common cause of intellectual disability in females after Down Syndrome. It is a neuronal developmental disease whose clinical symptoms begin to appear 6-18 months after birth and is characterized by an intellectual, social and motor skills impairments accompanied by autistic behaviours, such as repeated hand movements. It affects approximately 1 in 10,000 or 15,000 girls and is usually due to the presence of a mutation in the gene MECP2, an epigenetic gene which controls the activity of many other genes of the cell. Today there is no effective treatment for Rett syndrome, but the latest scientific developments indicate that we may be able to reverse the syndrome. To date, we have investigated various compounds that appear to improve some of the effects of the MECP2 mutation but we are still far away to understand that complex disease and to test all possible drugs. Help us to improve the life of girls affected by Rett Syndrome. Your donations of 10 or 25 Euros can make the difference. http://www.verkami.com/projects/9255-investigacion-de-nuevos-tratamientos-para-el-sindrome-de-rett


PEBC in "Cancer Research”, "Human Molecular Genetics” and “FEBS J”

Dr Manel Esteller

The research developed at the PEBC has been recognized in the prestigious journals Cancer Research”, “Human Molecular Genetics” y “FEBS J”. For further information: -A Comprehensive DNA Methylation Profile of Epithelial-to-Mesenchymal Transition. Carmona FJ, Davalos V, Vidal E, Gomez A, Heyn H, Hashimoto Y, Vizoso M, Martinez-Cardus A, Sayols S, Ferreira HJ, Sánchez-Mut JV, Morán S, Margelí M, Castella E, Berdasco M, Stefansson OA, Eyfjord JE, Gonzalez-Suarez E, Dopazo J, Orozco M, Gut IG, Esteller M. Cancer Res. Oct 1;74(19):5608-19, 2014. -Altered expression of the imprinted transcription factor PLAGL1 deregulates a network of genes in the human IUGR placenta. Iglesias-Platas I, Martin-Trujillo A, Petazzi P, Guillaumet-Adkins A, Esteller M, Monk D. Hum Mol Genet. pii: ddu347, 2014. -Gains of DNA methylation in myeloid terminal differentiation are dispensable for gene silencing but influence the differentiated phenotype. Vento-Tormo R, Alvarez-Errico D, Rodríguez-Ubreva J, Ballestar E. FEBS J. Sep 13. doi: 10.1111/febs.13045, 2014.


The European Research Council will fund a research of Dr. Manel Esteller to improve cancer diagnosis

Dr Manel Esteller

Barcelona, 21 September 2014. Dr. Manel Esteller, Director of the Cancer Epigenetics and Biology Program (PEBC) of the Bellvitge Biomedical Research Institute (IDIBELL), Professor of Genetics at the University of Barcelona and ICREA Research Professor has been awarded the 'Proof of Concept' grant by the European Research Council (ERC). The project aims to find alterations in the regulation of the least known regions of the genome that could serve as useful biomarkers for accurate diagnosis of human tumors. The recognition facilitates the transfer of this knowledge from laboratories to tests production that could be routinely used in clinical analysis. The project aims to create synergies between the academic and biomedical research companies, and in this way, expands the use of epigenetic maps to determine different types of uncertain nature cancer, collaboration started by Dr. Manel Esteller’s Group with Ferrer laboratories. This type of initiatives of the European Research Council aims to promote investments in Science as an economic driving force of the European Union.


PEBC in "Molecular Cell" and "Nature"

Dr Manel Esteller

In the early summer of 2014, the PEBC research has been recognized in the prestigious journals "Molecular Cell" and "Nature". For more information: -Liz J, Portela A, Soler M, GĂłmez A, Ling H, Michlewski G, Calin GA, Guil S, Esteller M. RNA-Directed Regulation of pri-miRNA Processing by a Long Noncoding RNA Transcribed from an Ultraconserved Region. Molecular Cell, doi: 10.1016/j.molcel.2014.05.005, 2014. -Ongen H, Andersen CL, Bramsen JB, Oster B, Rasmussen MH, Ferreira PG, Sandoval J, Vidal E, Whiffin N, Planchon A, Padioleau I, Bielser D, Romano L, Tomlinson I, Houlston RS, Esteller M, Orntoft TF, Dermitzakis ET. Putative cis-regulatory drivers in colorectal cancer. Nature, doi:10.1038/nature13602, 2014.


Back-to-back Discoveries of PEBC in Rett Syndrome

Dr Manel Esteller

We have at PEBC a long standing interest in rare disorders, particularly genetic syndromes affecting epigenetic genes. This is the case of Rett syndrome, the second most common cause of intellectual disability in women that it is associated with MeCP2 mutations. Two PEBC recent articles show how an excess of MeCP2 impairs neuronal function and how Parkinson’s drugs might be usel in reducing the phenotype of the mice that mimics the Rett syndrome. References: Petazzi P, Akizu N, Garcia A, Estarás C, Martinez de Paz A, Rodríguez-Paredes M, Martínez-Balbás M, Huertas D, Esteller M. An Increase in MeCP2 Dosage Impairs Neural Tube Formation. Neurobiology of Disease, 67C, 49-56, 2014. Szczesna K, de la Caridad O, Petazzi P, Soler M, Roa L, Saez MA, Fourcade S, Pujol A, Artuch-Iriberri R, Molero-Luis M, Vidal A, Huertas D, Esteller M. Improvement of the Rett Syndrome Phenotype in a Mecp2 Mouse Model Upon Treatment with Levodopa and a Dopa Decarboxylase Inhibitor. Neuropsychopharmacology, doi: 10.1038/npp.2014.136, 2014.



© 2008® | PEBC | Todos los derechos reservados |  WEBMAIL  |  INTRANET  |  FTP